Cardiff Oncology Inc CRDF
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-07-27 |
| Shares Out. | 77,800,000 |
| Website | cardiffoncology.com/ ↗ |
| Phone | 13026365400 |
| Employees | 31 |
| Revenue | $41,000 |
| Gross Profit | $41,000 |
| Net Income | -$12.3M |
| Free Cash Flow | -$37.5M |
| Total Assets | $49.2M |
| Total Liabilities | $14.5M |
| Equity | $34.7M |
About Cardiff Oncology Inc
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Cardiff Oncology Inc is a publicly traded company under the ticker symbol CRDF on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)